{"id":"W2033119689","doi":"10.1038/bjc.2013.735","title":"A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Neurological Complications and Syndromes","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Regeneron Pharmaceuticals; Sanofi","keywords":"Medicine; Aflibercept; Pemetrexed; Internal medicine; Nausea; Lung cancer; Adverse effect; Phases of clinical research; Oncology; Cisplatin; Progressive disease; Gastroenterology; Surgery; Chemotherapy; Bevacizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002298567,0.001526312,0.002649154,0.0004442726,0.000382315,0.0009157346,0.001197366,0.001107042,0.003231068],"category_scores_gemma":[0.001479657,0.0007261722,0.00142052,0.0005359338,0.0009751437,0.0008314608,0.0004321845,0.003458669,0.0008051966],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001030134,"about_ca_system_score_gemma":0.001543952,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000710429,"about_ca_topic_score_gemma":0.001675515,"domain_scores_codex":[0.9991108,0.0004896466,0.00005482224,0.0001389626,0.00008908403,0.0001167755],"domain_scores_gemma":[0.9988521,0.0001920291,0.0003239674,0.00008071565,0.00006389702,0.0004871473],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7910669,0.07840488,0.01305583,0.001173092,0.002354407,0.000281344,0.000389575,0.002253392,0.0419815,0.0001266675,0.001902241,0.06701011],"study_design_scores_gemma":[0.6245638,0.3612029,0.01034783,0.00001687901,0.0004075765,0.0002045586,0.00003282752,0.0005917106,0.001641957,0.00004428203,0.0009290649,0.00001670027],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939811,0.001819756,0.0004292102,0.0002599799,0.0000737373,0.002430375,0.0003403867,0.0000474197,0.0006180452],"genre_scores_gemma":[0.9927999,0.001262368,0.001442958,0.000442062,0.000143729,0.002136247,0.0009834352,0.00002031996,0.0007690107],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003231068,"threshold_uncertainty_score":0.01215613,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008271514152304687,"score_gpt":0.2689566194956499,"score_spread":0.2606851053433452,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}